Novo Nordisk is not a cyclical stock in the traditional sense — it does not follow commodity prices, interest rates, or PMI. But it follows a product cycle that is just as important to understand: the pharmaceutical innovation cycle, where blockbuster drugs create periods of extraordinary growth followed by patent cliffs, competition, and multiple compression. Novo's GLP-1 dominance is the biggest drug cycle story in a generation.
Novo Nordisk had been a leading insulin manufacturer for decades — a steady, profitable, but unremarkable pharmaceutical business. The transformation came from GLP-1 receptor agonists: Ozempic (semaglutide for diabetes) and Wegovy (semaglutide at higher dose for obesity). These drugs do not just manage symptoms — they address root causes of metabolic disease with clinical outcomes that no prior drug achieved. The obesity market alone is estimated at over one billion people globally.
Between 2020 and 2024, Novo Nordisk's market capitalisation grew from approximately DKK 600 billion to over DKK 4 trillion — making it larger than the entire Danish GDP and briefly the largest company in Europe by market cap. This extraordinary re-rating was driven by the realisation that GLP-1 drugs represent a genuine step change in treating chronic disease.
Eli Lilly's tirzepatide (Mounjaro/Zepbound) has demonstrated superior weight loss outcomes versus semaglutide in clinical trials, taking significant market share in the US since its 2023 launch. AstraZeneca, Roche, Pfizer, and numerous biotech companies are developing next-generation obesity drugs — some oral rather than injectable. The critical question for Novo investors is whether semaglutide's first-mover advantage, manufacturing scale, and physician familiarity can be sustained against this competitive onslaught.
Novo Nordisk's primary constraint in 2023–2024 was not demand but supply. Global manufacturing capacity for injectable GLP-1 drugs was insufficient to meet demand — creating shortages, rationing, and pricing power. Novo has invested over DKK 100 billion in new manufacturing capacity, primarily in Denmark and the United States. As this capacity comes online between 2024 and 2027, supply constraints ease — removing the scarcity premium from pricing while enabling volume growth.
Novo Nordisk should be valued on long-term free cash flow rather than near-term P/E, given the multi-decade nature of its drug assets. The key variables are: peak GLP-1 market size, Novo's sustainable market share, operating margins at scale, and the timeline to biosimilar competition. At 25x forward earnings, Novo prices in sustained growth without the full obesity market opportunity. At 40x+, the market is pricing in near-perfect execution of the obesity opportunity.
Signycle monitors cycle indicators across Nasdaq Copenhagen, Stockholm and Oslo Børs — and alerts you when buy or sell signals trigger.
Get Early Access